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Abstract We have expressed active full-length human inducible 
nitric oxide synthase (INOS) in E. coli. Expression required co- 
expression with cahnodulin, a particularly tight-binding cofactor. 
The extracts also required tetrahydrobiopterin to display activity. 
Specific activity of the purified recombinant iNOS was similar 
to iNOS purified from murine macrophages. This result indicates 
that no special processing events unique to eucaryotic cells are 
necessary for iNOS activity. 
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1. Introduction 
Nitric oxide (NO) is an important mediator of many biolog- 
ical responses [ 1,2]. Production of NO from arginine and O2 is 
catalyzed by NO synthase (NOS). There are three known 
isoforms of NOS, named for their initial cloning source: endo- 
thelial (eNOS), brain (bNOS), and macrophage or inducible 
(INOS). These three proteins, homodimers with subunit molec- 
ular masses of 1255150 kDa, share significant homology [3,4]. 
All contain heme, FAD, FMN and tetrahydrobiopterin (THB). 
eNOS and bNOS, constitutive enzymes involved in signaling, 
are regulated by calciumlcalmodulin. In contrast, expression of 
iNOS requires cytokine induction. The iNOS enzyme activity 
is not regulated by calcium even though it contains tightly 
bound calmodulin. The level of NO production by iNOS is 
considerably greater than that of eNOS and bNOS. High levels 
of NO are cytotoxic, leading to the physiologic role of iNOS 
in immunological defense, and its pathologic role in inflamma- 
tory disease. 
Natural sources of the NOS isoforms generally yield low 
amounts of protein. High level expression of bNOS has been 
achieved in human 293 embryonic kidney cells [5] and Spodop- 
terafrugiperda insect cells after infection with baculovirus con- 
taining the bNOS cDNA [6]. In this paper, we describe the high 
level expression of human iNOS in Escherichia coli. Expression 
of iNOS is dependent on the co-expression of calmodulin, and 
its activity is dependent on exogenous addition of THB. 
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2. Materials and methods 
2.1. Cloning of human iNOS 
Human iNOS was cloned from DLD cells [7] by reverse transcription 
of total RNA using a cDNA Cvcle kit (Invitroeen) and an olieo dT 
primer followed by-PCR amplifi;cation using four sets of oligonicleo- 
tide primers. A full-length iNOS cDNA was assembled from the prod- 
ucts of the four PCR reactions to make piNOS17-10. 
2.2. Bacterial expression vector for iNOS 
The iNOS cDNA was cloned into pJF123, which contains a tat 
promoter-lac operator, a IacP gene, and a pUC19 ampicillin gene and 
origin. To accent the iNOS cDNA. uJF123 was modified to add annro- 
priately placed- NcoIIXbaI sites making pJF402. Vectors piNOSi?~lO 
and pJF402 were digested with NcoIlXbaI (New England Biolabs), 
appropriate fragments isolated, and ligated to make the iNOS expres- 
sion vector piNOS48816. 
2.3. Isolation of the human calmodulin cDNA and expression in E. coli 
1 ,ug of brain polyA’ RNA (Clontech) was reverse transcribed with 
an olieo dT mimer usine a cDNA Cvcle kit (Invitroaen) followed bv 
polymirase chain reaction amplification with‘ 5’ primer ‘GACGCCA- 
TGGCTGA-CCAACTGACTGAAGAG and 3’ primer CCATGGA- 
TCCTCACTTTGCTGTCATTTGT-AC, which added an NcoI site at 
the ATG start and a BamHI site downstream of the stop codon. The 
PCR product was cut with NcoIIBamHI and ligated into pSL1190 
(Pharmacia), yielding pSLll90cam- 12. 
A calmodulin expression vector was created by ligating the calmod- 
ulin cDNA (from pSLl190cam-12 cut with NcoIIBamHI) with pJF402, 
making pCam5-2. The tat promoterllac operator + calmodulin + laci* 
fragment (from pCam5-2 cut with Xr&rI/AvaI) was ligated into 
oACYCl84 181 to make uACYC:Cam221. Transformine E. coli JS5 
?BioRad) wih’this vecto; yielded IPTG-inducible expreszon of calm- 
odulin, shown immunologically using an anticalmodulin monoclonal 
antibody (Upstate Biotechnology) and by Coomassie staining after 
SDS-PAGE. 
2.4. Purification of iNOS in E. coli 
E. coli JS5 containing piNOS48-16 + pACYC:CamZ-1 was grown 
at 30°C in 20 1 of Luria broth to an O.D.,,, of 1.0. IPTG (IOOpM) was 
added and the culture was grown overnight. Cells were harvested, 
resuspended in 20 mM HEPES pH 7.5, I-mM DTT, 1 mM PMSF, 
1 mM EDTA. 2 uM THB (Biomol Research Labs). 2 uM hemin (Siama). 
and 10 PM each of FAD‘ and FMN (Buffer Ajto’O.D.,,,=ltjO,-then 
broken by sonication. A cell-free supernatant was made 20% (w/v) 
ammonium sulfate. Following centrifugation, the supernatant was ad- 
justed to 40% ammonium sulfate. The resulting protein pellet was 
resuspended in buffer A minus EDTA and flavins (Buffer B) to l-2 
mg/ml and conductivity ~6 mS. CHAPS (Sigma) was then added to 
0.5% (w/v) and the sample was loaded onto a 300-ml Q Sepharose 
column (Pharmacia) equilibrated in buffer B + 50 mM NaCl and 0.1% 
CHAPS. The charged column was washed, then eluted using a 3-1 
gradient in buffer B and 0.1% CHAPS from 50 to 300 mM NaCl. The 
iNOS activity peak was pooled and concentrated with 50% saturated 
ammonium sulfate. The pellet was redissolved in 40 ml of buffer 
B + 100 mM NaCl and was loaded onto a lOOO-ml Sephacryl 300 
[Pharmacia] column. iNOS containing fractions (>90% pure) were 
pooled. 
2.5. iNOS assay 
iNOS activity was measured by the conversion of radioactive argin- 
ine to citrulline [9]. Reactions (50~1) contained 20 mM HEPES pH 7.5, 
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0.1 mM DTT, 20 PM FAD, 20 PM FMN, 10 PM THB, 20 PM hemin, 
1 mM NADPH, 2 mg/ml BSA, 50 PM cold arginine and 1 PM 
[3H]arginine (60 CiImmol; Amersham). After incubation at 37°C for 
30-60 min, reactions were stopped by adding 50 ~1 of 0.1 M sodium 
citrate pH 5.5, 100 fiM IV”-methyl-L-arginine (NMMA). The reaction 
mix was then passed through 100 ~1 of Dowex resin (AGSO-X8) in a 
96-well filtration (Millipore) plate to separate citrulline (unbound) from 
arginine (bound). The filtrate was counted in 1450 Microbeta Plus 
liquid scintillation counter (Wallac). All assays contained sufficient 
enzyme to convert lO_20% of the tritiated arginine to product. Activi- 
ties are reported in U/ml, with U defined as pmol of citrulline formed/ 
min. To remove any cold arginine, samples of E. c&cell lysates express- 
ing iNOS activity were desalted on a G-25 column prior to assay. 
3. Results 
3. I. Expression of iNOS in E. coli 
Expression of human iNOS from vector piNOS48-16 in 
E. coli resulted in very low NOS activity (see Fig. 1). SDS-PAGE 
and Western blotting showed similarly low expression of solu- 
ble iNOS protein. Calmodulin has been shown to be very tightly 
associated with murine iNOS [lo]; it is not removed by EGTA 
or purification. We reasoned that co-expression of human 
iNOS and calmodulin might be required for proper iNOS fold- 
ing. We cloned human calmodulin, assembled an expression 
vector compatible with co-transfection with piNOS48-16, and 
compared NOS activity in cells expressing iNOS with and with- 
out calmodulin co-expression. Fig. 1 shows that the iNOS activ- 
ity with calmodulin co-expression was approximately lOO-fold 
higher than without co-expression, reaching 3000-5000 U/mg 
in the crude extract. Assuming a specific activity of 1 x IO6 
U/mg [ll], the expression level is approximately 0.3-0.5% of 
total soluble protein. This was confirmed by SDS-PAGE of the 
active extract (Fig. 2) showing a 125-kDa iNOS band not seen 
in a negative control. 
A B C D E F 
Fig. 1. Comparison of iNOS expression in E. coli with and without 
co-expression of calmodulin. The assays were run on crude extracts 
matched to the same protein concentration and assayed as described 
in section 2 except 1 PM undiluted labeled arginine was used. Column 
A, iNOS + calmodulin co-expression extract; B, same as A but with 10 
&ml calmodulin added; C, iNOS alone extract; D, same as C but with 
10 pg/ml calmodulin added; E, negative control extract; F, same as E 
but with 10 &ml calmoduhn added. Results were normalized to col- 
umns A and B (which gave identical activities of 27,000 pmol/min.-mg.) 
and are the average of three assays. 
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Fig. 2. SDS-PAGE of human iNOS expression in E. coli. Lane 1 is a 
molecular mass marker set (sizes in kDa on the left margin): lane 2 is 
piNOS48&16 + pACYC:cam2-1 co-expressed in E. coli; lane 3 is a 
negative control. The arrow indicates the position of the human iNOS 
polypeptide (see lane 2). The polypeptide is absent in the negative 
control (lane 3). 
3.2. Characterization of E. coli expressed iNOS 
The specific activity of iNOS in the crude cell supernatant 
was estimated to be 500-1000 nmol citrulline/min/mg of iNOS, 
based on the amount of iNOS polypeptide on an SDS-poly- 
acrylamide gel (relative to known BSA samples). This compares 
favorably with 1000 nmol/min/mg determined for purified mur- 
ine iNOS [ 111. The iNOS activity in the crude cell extract exhib- 
ited a Km for arginine of 8 ,LLM, similar to that determined for 
murine iNOS [ Ill. The activity was unaffected by 1 mM EGTA 
or 1 mM CaCl, f 10 yglml calmodulin. The iNOS activity was 
totally dependent on exogenously added THB (Fig. 3), with 
half-maximal activity seen at 120 nM THB. Activity was not 
dependent on the other iNOS cofactors. The effect of iNOS 
inhibitors (NMMA, imidazole, and aminoguanidine) on E. coli- 
derived iNOS was similar to that displayed by recombinant 
iNOS expressed in human 293 embryonic kidney cells (X. Fan, 
pers. commun.), with IC,, values of 2 PM, 120,~~M, and 80 PM, 
respectively. 
3.3. PuriJcation of iNOS 
iNOS was purified to >90% purity as shown in Table 1. The 
purification consisted of an ammonium sulfate precipitation 
followed by a Q-Sepharose ion-exchange chromatography and 
Sephacryl S300 gel filtration. Characterizing the individual 
iNOS pools by SDS-PAGE (Fig. 4, note lane 5) shows that 
calmodulin copurifies with the human iNOS protein (verified 
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Fig. 3. The effect of THB on iNOS activity in E. coli extracts co- 
expressing iNOS and calmodulin. The cell were broken and processed 
as described in section 2 but without added THB. The assay was run 
with varying amounts of THB from 50 pM to 200 ,uM. Activity is given 
in countslmin (cpms) of citrulhne. 
immunologically). Overall yield of iNOS activity was 24%. The 
specific activity of pure material (fractions from the leading 
edge of the S300 column) was 600,000 Ulmg. This compares 
favorably with pure murine iNOS at l,OOO,OOO Ulmg [l l] and 
rat bNOS at 230,000 Ulmg [5]. The yield of iNOS from 20 1 of 
cells (32 g starting protein in the extract) was 3040 mg. 
4. Discussion 
In this report, we show expression of soluble, active iNOS 
was dependent on its co-expression with calmodulin. We postu- 
late that the extremely tight association of calmodulin with 
iNOS serves a structural purpose in allowing iNOS to fold 
correctly. This is in contrast to eNOS and bNOS where calmod- 
ulin-binding is regulated by calcium; calmodulin is freely disso- 
ciable if calcium is removed by EGTA. E. coli expressed iNOS 
appears to have the same specific activity as murine iNOS, a 
similar K,,, for arginine, and similar ZC,,, values for three iNOS 
inhibitors as does mammalian-derived iNOS. This indicates 
that no mammalian-specific modification of iNOS is necessary 
for NOS activity. The enzyme activity was completely depend- 
ent on added THB with a half-maximal concentration of 120 
nM. The binding constant of THB for bNOS has been shown 
to be 31 nM and 250 nM in the presence and absence of 100 
PM arginine, respectively [ 121. 










Fig. 4. SDS-PAGE of the purification of human iNOS from E. co/i. 
Lane 1, molecular mass marker set (sizes in kDa in the left margin); lane 
2, cell lysate; lane 3, 40% ammonium sulfate precipitate; lane 4, Q 
Sepharose pool; and lane 5, pool from the front half of the S300 iNOS 
peak. The arrow indicates iNOS protein. 
effects of NO would be expected to make its stable, unregulated 
expression in cells very difficult. To date, it has not been possi- 
ble to make a stably transfected mammalian cell line expressing 
iNOS at high levels, although we have developed transient 
systems. Expression of iNOS has only been described in a 
baculovirus system [6], a transient expression system in which 
long-term survival of the cells expressing iNOS is not required. 
Expression of inactive iNOS in E. coli lacking THB overcomes 
the toxicity problems. In addition, the level of expression we 
report, 3000-5000 U/mg, is higher than the level reported in a 
baculovirus expression system [ 131 of 350 U/mg. In conclusion, 
the expression of human iNOS in E. coli should greatly aid 
future studies of the enzyme. We have demonstrated that pure 
iNOS can be obtained by a simple procedure and at yields 
compatible with spectral and structural analysis. The complete 
dependence of E. coli expressed iNOS on THB offers a system 
to study the role of this cofactor in the catalytic mechanism. 
Table 1 
Purification of human iNOS 
Sample Volume Protein cont. Total protein Total activity Specific act. 
(ml) (mg/ml) (mg) (U) (Wmn) 
Cell lysate 2600 12.5 32475 78,600,OOO 2,420 
40% amm. sul. ppt. 3300 1.2 3960 77,600,OOO 19,600 
Q Sepharose pool 470 0.35 165 23,000,OOO 149,000 
s300 pool 180 0.22 40 19,200,OOO 480,000 
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